GB2085297A - Composition for treating psoriasis of the fingernails - Google Patents

Composition for treating psoriasis of the fingernails Download PDF

Info

Publication number
GB2085297A
GB2085297A GB8032432A GB8032432A GB2085297A GB 2085297 A GB2085297 A GB 2085297A GB 8032432 A GB8032432 A GB 8032432A GB 8032432 A GB8032432 A GB 8032432A GB 2085297 A GB2085297 A GB 2085297A
Authority
GB
United Kingdom
Prior art keywords
composition
psoriasis
nail polish
lotion
nail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8032432A
Other versions
GB2085297B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB8032432A priority Critical patent/GB2085297B/en
Publication of GB2085297A publication Critical patent/GB2085297A/en
Application granted granted Critical
Publication of GB2085297B publication Critical patent/GB2085297B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition for treating psoriasis of the nails comprising applying conventional nail polish containing an anti-psoriasis effective amount of a topical steroid e.g. fluorandrenolide or betamethasone valerate.

Description

SPECIFICATION Composition for treating psoriasis of the fingernails This application relates to a composition for treating psoriasis of the fingernails.
Psoriasis is a chronic relapsing papulosquamous skin disease which can also affect nails. Nail involvement resembles a fungus infection with stipping, separation of the distal margin, nail loss, scales under the nail plate, thickening and discoloration and is seen in anywhere from ten to fifty percent of psoriasis patients.
While there are a limited number of effective anti-psoriasis agents, it is far more difficult to treat psoriasis of the nails than that of the skin.
Treatment of psoriasis (skin) can include daily removal of the scales by applying soap and water and scrubbing gently with a soft brush, followed by the application of a keratolytic ointment.
Topical steroids, particularly 0.01 to 0.025% of fluocinolene acetonide, 0.25% fluorandrenolide and 0.05% triamcinolene acetonide creams have replaced many previous local treatments. The topical steroids are most effective if covered with a polyethylene film, Saran Wrap (R.T.M.) or Handi Wrap (R.T.M.), which preferably are sealed with tape. Thin polyethylene gloves are used for treating the hands and fingers.
Another method involving topical steroids are the use of an inconspicuous, transparent, plastic surgical tape containing fluorandrenolide, Cordrant (R.T.M.) tape sold by Dista Products Company, Division of Eli Lilly and Company, Indianapolis, Indiana 46206.
Generally speaking, while there are methods which are effective in treating psoriasis of the skin, attempts to treat nail involvement have failed miserably. Topically applied steroids are generally without effect.
Accordingly, the present invention provides an antipsoriatic nail polish composition comprising nail polish containing an effective amount of a topical cortico-steroid.
I have found that excellent results are obtained when this composition is used for treatment of psoriasis of the fingernails.
In the practice of the present invention, topical steroids such as betamethhasone valerate is sold under the trademark Valisone (R.T.M.) by Schering Corporation, Galloping Hill Road, Kenilworth, New Jersey 07033. Valisone is available in aerosol 0.15% w/w reduced strength cream (0.01%) and 0.1% cream, ointment and lotion. In the practice of the present invention, when Valisone is used as the topical steroid, it is preferred to use the 0.1% lotion which contains in each gram betamethasone valerate equivalent to 1.0 mg. of betamethasone (9 fluoro-1 1 17, 21 -trihydroxy-1 6methyIprngna-1 4- diene-3,20-diene 17 valerate) in a vehicle consisting of isopropyl alcohol (47.5%) and water slightly thickened with carboxy vinyl polymer, the pH adjusted to approximately 4.7 with sodium hydroxide.
Betamethasone valerate is effective in relieving the inflammatory manifestations of corticoidresponsive dermatoses because of its antiinflammatory, antipruretic and vasoconstrictive actions.
Fluorondrenolide (6a-fluoro-16a- hydroxycortisone 16, 17-acetonide) is sold by Dista Products Company, Division of Eli Lilly and Company, P.O. Box 1407, Indianapolis, Indiana 46206 and is available as a cream, ointment or lotion in full (0.05%) or half (0.025%) preparations. Cordran also is primarily effective as a topical corticosteroid because of its anti-flammatory, antipruretic and vasoconstrictive actions.
Generally speaking, in the practice of the present invention, a topically effective corticosteroid having anti-inflammatory, anti-pru retic and vasoconstrictive actions, preferably in lotion form, is mixed with commercially available nail polish such as Revlon clear nail polish in an anti-psoriasis effective amount, preferably in a 50:50 mixture and said mixture is peroidically applied to the affective nails preferably at least once daily and more often in severe, intractable cases.
The following examples further illustrate the present invention.
Example 1 A nail polish composition useful in treating psoriatic nails was prepared by mixing 0.1% Valison lotion with Revlon clear nail polish in a 50:50 mixture.
Example 2 The composition of Example 1 was applied twice daily to the nails of a 36 year old male psoriasis patient with psoriatic nail involvement with noticeable improvement after 8 weeks.
Example 3 The composition of Example 1 was applied twice daily to the psoriatic nails of a 50 year old patient.
There was complete clearing of the nail involvement within eight weeks.
Example 4 The composition of Example 1 was applied once daily to a 55 year old female patient with psoriatic nails with noticeable improvement after 6 weeks.
Example 5 A nail polish compositio was prepared as in Example 1, using 0.05% Cordran lotion instead of Valisone lotion. The composition was applied to the psoriatic nails of psoriasis patients with similar results of Examples 2-4.
It will be understood by those skilled in the art that any commercial nail polish, colored or clear, can be used in the practice of the invention and while Cordran and Valisone lotions have been used byway of example, any topical steroid having antiinflammatory, antipruretic and vasoconstructive activities normally used in the treatment of psoriasis can be employed in the practice of this invention.
1. An antipsoriatic nail polish composition com
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (7)

**WARNING** start of CLMS field may overlap end of DESC **. SPECIFICATION Composition for treating psoriasis of the fingernails This application relates to a composition for treating psoriasis of the fingernails. Psoriasis is a chronic relapsing papulosquamous skin disease which can also affect nails. Nail involvement resembles a fungus infection with stipping, separation of the distal margin, nail loss, scales under the nail plate, thickening and discoloration and is seen in anywhere from ten to fifty percent of psoriasis patients. While there are a limited number of effective anti-psoriasis agents, it is far more difficult to treat psoriasis of the nails than that of the skin. Treatment of psoriasis (skin) can include daily removal of the scales by applying soap and water and scrubbing gently with a soft brush, followed by the application of a keratolytic ointment. Topical steroids, particularly 0.01 to 0.025% of fluocinolene acetonide, 0.25% fluorandrenolide and 0.05% triamcinolene acetonide creams have replaced many previous local treatments. The topical steroids are most effective if covered with a polyethylene film, Saran Wrap (R.T.M.) or Handi Wrap (R.T.M.), which preferably are sealed with tape. Thin polyethylene gloves are used for treating the hands and fingers. Another method involving topical steroids are the use of an inconspicuous, transparent, plastic surgical tape containing fluorandrenolide, Cordrant (R.T.M.) tape sold by Dista Products Company, Division of Eli Lilly and Company, Indianapolis, Indiana 46206. Generally speaking, while there are methods which are effective in treating psoriasis of the skin, attempts to treat nail involvement have failed miserably. Topically applied steroids are generally without effect. Accordingly, the present invention provides an antipsoriatic nail polish composition comprising nail polish containing an effective amount of a topical cortico-steroid. I have found that excellent results are obtained when this composition is used for treatment of psoriasis of the fingernails. In the practice of the present invention, topical steroids such as betamethhasone valerate is sold under the trademark Valisone (R.T.M.) by Schering Corporation, Galloping Hill Road, Kenilworth, New Jersey 07033. Valisone is available in aerosol 0.15% w/w reduced strength cream (0.01%) and 0.1% cream, ointment and lotion. In the practice of the present invention, when Valisone is used as the topical steroid, it is preferred to use the 0.1% lotion which contains in each gram betamethasone valerate equivalent to 1.0 mg. of betamethasone (9 fluoro-1 1 17, 21 -trihydroxy-1 6methyIprngna-1 4- diene-3,20-diene 17 valerate) in a vehicle consisting of isopropyl alcohol (47.5%) and water slightly thickened with carboxy vinyl polymer, the pH adjusted to approximately 4.7 with sodium hydroxide. Betamethasone valerate is effective in relieving the inflammatory manifestations of corticoidresponsive dermatoses because of its antiinflammatory, antipruretic and vasoconstrictive actions. Fluorondrenolide (6a-fluoro-16a- hydroxycortisone 16, 17-acetonide) is sold by Dista Products Company, Division of Eli Lilly and Company, P.O. Box 1407, Indianapolis, Indiana 46206 and is available as a cream, ointment or lotion in full (0.05%) or half (0.025%) preparations. Cordran also is primarily effective as a topical corticosteroid because of its anti-flammatory, antipruretic and vasoconstrictive actions. Generally speaking, in the practice of the present invention, a topically effective corticosteroid having anti-inflammatory, anti-pru retic and vasoconstrictive actions, preferably in lotion form, is mixed with commercially available nail polish such as Revlon clear nail polish in an anti-psoriasis effective amount, preferably in a 50:50 mixture and said mixture is peroidically applied to the affective nails preferably at least once daily and more often in severe, intractable cases. The following examples further illustrate the present invention. Example 1 A nail polish composition useful in treating psoriatic nails was prepared by mixing 0.1% Valison lotion with Revlon clear nail polish in a 50:50 mixture. Example 2 The composition of Example 1 was applied twice daily to the nails of a 36 year old male psoriasis patient with psoriatic nail involvement with noticeable improvement after 8 weeks. Example 3 The composition of Example 1 was applied twice daily to the psoriatic nails of a 50 year old patient. There was complete clearing of the nail involvement within eight weeks. Example 4 The composition of Example 1 was applied once daily to a 55 year old female patient with psoriatic nails with noticeable improvement after 6 weeks. Example 5 A nail polish compositio was prepared as in Example 1, using 0.05% Cordran lotion instead of Valisone lotion. The composition was applied to the psoriatic nails of psoriasis patients with similar results of Examples 2-4. It will be understood by those skilled in the art that any commercial nail polish, colored or clear, can be used in the practice of the invention and while Cordran and Valisone lotions have been used byway of example, any topical steroid having antiinflammatory, antipruretic and vasoconstructive activities normally used in the treatment of psoriasis can be employed in the practice of this invention. CLAIMS
1. An antipsoriatic nail polish composition com prising nail polish containing an effective amount of a topical corticosteroid.
2. The composition of Claim 1, wherein said corticosteroid comprises 50% by volume of said composition.
3. The composition of Claim 1, wherein said topical corticosteroid is a fluorinated steroid.
4. The composition of Claim 1, wherein said corticosteroid is selected from the group consisting of fluorandrenolide or betamethasone valerate.
5. The composition of Claim 4, wherein said corticosteroid is 0.1% betamethasone valerate lotion.
6. The composition of Claim 4, wherein said corticosteroid is 0.05% fluorandrenolide lotion.
7. An antipsoriatic nail polish composition according to claim 1 and substantially as herein described.
GB8032432A 1980-10-08 1980-10-08 Composition for treating psoriasis of the fingernails Expired GB2085297B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB8032432A GB2085297B (en) 1980-10-08 1980-10-08 Composition for treating psoriasis of the fingernails

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8032432A GB2085297B (en) 1980-10-08 1980-10-08 Composition for treating psoriasis of the fingernails

Publications (2)

Publication Number Publication Date
GB2085297A true GB2085297A (en) 1982-04-28
GB2085297B GB2085297B (en) 1984-06-13

Family

ID=10516552

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8032432A Expired GB2085297B (en) 1980-10-08 1980-10-08 Composition for treating psoriasis of the fingernails

Country Status (1)

Country Link
GB (1) GB2085297B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247142A1 (en) * 1985-11-04 1987-12-02 Dermatological Products Of Tex Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same.
WO1997034644A1 (en) * 1996-03-16 1997-09-25 Hoechst Aktiengesellschaft Topical formulations for the treatment of nail psoriasis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247142A1 (en) * 1985-11-04 1987-12-02 Dermatological Products Of Tex Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same.
EP0247142A4 (en) * 1985-11-04 1988-09-07 Dermatological Products Texas Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same.
WO1997034644A1 (en) * 1996-03-16 1997-09-25 Hoechst Aktiengesellschaft Topical formulations for the treatment of nail psoriasis

Also Published As

Publication number Publication date
GB2085297B (en) 1984-06-13

Similar Documents

Publication Publication Date Title
Castor et al. The local action of adrenocortical steroids on epidermis and connective tissue of the skin
US4486450A (en) Method of treating psoriatic skin and composition
US3856934A (en) Skin depigmentation
JP4681087B2 (en) Combination of acidic protease enzyme and acidic buffer and use thereof
DE2046119C2 (en) Means for treating acne
AU609090B2 (en) Composition for treatment of acne
JP3534751B2 (en) Treatment of acne or pseudofolliculitis
US4250164A (en) Method of treating psoriasis of the nails and composition
US4352794A (en) Beta-cyclodextrin as anti-acne agent
WO1999008651A1 (en) Skin care compositions and use
Lowe et al. Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin
Lassus et al. A dimethoxynaphthalene derivative (RS‐43179 gel) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis
JPH06128159A (en) External agent
GB2085297A (en) Composition for treating psoriasis of the fingernails
CA1144482A (en) Corticosteroid in nail polish
US5435997A (en) Topical agent and method for the treatment of pseudofolliculitis barbae
DK165938B (en) TOPIC AGENT FOR TREATMENT OF NON-INFLAMMATORY ACNE
US6843983B2 (en) Shaving preparations and methods for the prevention and treatment of pseudofolliculitis barbae
EP0086228B1 (en) Use of carbamide peroxide for the manufacture of a medicament for treatment of acne vulgaris
EP0342524B1 (en) Medicine for treating mycotic, microbial and other tissue damaging and pathological manifestations and deformations of tissue
US4466956A (en) Method of therapy for oral herpes simplex
US5240945A (en) Method and compositions for treating acne
JPS6410495B2 (en)
EP0095512B1 (en) Antipsoriatic composition
US4133893A (en) Topical treatment of skin diseases

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee